Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 5 January 2026 - 6 January 2026

Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

NEW YORK, January 6, 2026, 12:28 EST — Regular session Shares of Moderna Inc (MRNA.O) were up 10.7% at $35.60 in midday trading on Tuesday after BofA Global Research raised its price objective on the vaccine maker. The stock touched a session high of $36.25. Reuters The jump comes as investors weigh whether Moderna can turn its mRNA platform into steadier, seasonal revenue after the post-pandemic drop in COVID-19 vaccine demand. Traders have been sensitive to shifts in sell-side views as the company leans on new product launches and tighter spending to narrow losses. On Monday, Moderna said it filed
6 January 2026
··
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

New York, Jan 6, 2026, 11:34 AM EST — Regular session Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com The update lands amid a scramble for new obesity treatments that can add to GLP-1 drugs — a fast-growing market where investors now weigh not just pounds lost, but what kind of weight comes off. Many patients and doctors want therapies that
6 January 2026
···
Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

New York, January 6, 2026, 10:55 EST — Regular session Eli Lilly and Company (LLY) shares rose about 1.6% on Tuesday after Nimbus Therapeutics announced a research and licensing agreement with the drugmaker aimed at developing an oral obesity treatment. Lilly was trading at $1,057.80 in New York morning trade, after moving between $1,040.15 and $1,070.77 earlier in the session. Reuters The tie-up matters because pills could widen access and intensify competition in weight-loss medicines, a market where convenience and price are becoming as important as results. Investors have watched the sector shift from supply constraints toward a more consumer-style
6 January 2026
··
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

New York, Jan 6, 2026, 10:40 EST — Regular session Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14. The move extends a rebound sparked by the U.S. rollout of a pill version of Wegovy, a franchise that has become central to how investors value the Danish drugmaker’s growth story. The launch matters now because the obesity market is shifting from a supply-driven boom to a fight over price, convenience and who pays. Novo needs the pill to widen demand without triggering a margin-eroding price
6 January 2026
···
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

New York, January 6, 2026, 09:49 EST — Regular session Alumis Inc (ALMS) shares jumped about 129% in early trade on Tuesday after the drugmaker reported positive late-stage data for its psoriasis pill, envudeucitinib. The stock was at $19.04, up from a previous close of $8.31, after touching $22.30 to set a new 52-week high, Google Finance data showed. Google The readout is a pivotal moment for the South San Francisco-based biopharma, which is trying to deliver biologic-like skin clearance in a pill. A clean Phase 3 package can pull forward the regulatory clock and reset expectations for the company’s
6 January 2026
··
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

NEW YORK, Jan 6, 2026, 08:02 EST — Premarket AbbVie shares were flat in premarket trading on Tuesday after the drugmaker said Health Canada had approved its hepatitis C pill Maviret for both acute and chronic infection. AbbVie stock last traded at $220.18. The expanded label matters because it opens the door to treatment soon after diagnosis, when infections are recent and transmission risk can be higher. The company said the eight-week, pan-genotypic regimen — meaning it works across major virus types — is now cleared in Canada for acute and chronic hepatitis C virus (HCV). AbbVie fell 3.98% on
6 January 2026
··
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

New York, January 6, 2026, 07:27 EST — Premarket Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public The launch lands as investors debate how fast the obesity-drug boom can grow without forcing deeper price cuts. It also puts fresh focus on political pressure in Washington to bring down prices for widely used weight-loss medicines. Novo’s push into pills matters because it aims at patients who
6 January 2026
···
Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

New York, January 5, 2026, 21:51 EST — Market closed Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. Pfizer The San Francisco gathering is a major kickoff for healthcare investing, and it comes as Pfizer tries to convince markets it can replace fading pandemic-era revenue. The company’s initial 2026 outlook, issued in December, came in below analysts’ estimates. JPMorgan Chase That timing matters because Pfizer is navigating lower sales of
6 January 2026
··
Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

New York, January 5, 2026, 21:32 (EST) — Market closed Merck & Co shares dipped in late trading on Monday after U.S. health officials rewrote the childhood and adolescent immunization schedule, including a change to a one-dose recommendation for the human papillomavirus (HPV) vaccine. Merck (MRK.N) closed up 0.93% at $107.44 and was last down 0.22% at $107.20 after the bell. Yahoo Finance The shift matters for Merck because Gardasil 9 is the only HPV vaccine available for use in the United States, and the CDC’s guidance helps shape how physicians counsel families. Even modest changes in dosing guidance can
6 January 2026
···
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

New York, Jan 5, 2026, 21:27 EST — Market closed AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high. The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%. Yahoo Finance AbbVie also put a near-term spotlight on its calendar, saying it will present
6 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

New York, January 5, 2026, 5:47 PM ET — After-hours Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post The drop matters because investors have priced Lilly as a long-duration obesity winner, with expectations anchored to rapid growth in demand and tight supply. Any new sign that the market is shifting toward cheaper oral options can force a reset in assumptions about pricing power. GLP-1 drugs,
6 January 2026
···
Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

New York, January 5, 2026, 15:35 EST — Regular session Merck & Co (NYSE:MRK) shares edged up on Monday as investors looked ahead to the drugmaker’s appearance at the annual J.P. Morgan Healthcare Conference next week. The stock was up 0.3% at $106.80 at 3:35 p.m. EST, after earlier reaching $108.30. The conference is a closely watched early-year marker for healthcare stocks, often offering the first public read on management priorities before earnings season ramps up. Merck’s share performance has also been tied to investor confidence in its longer-term growth story, led by the cancer immunotherapy Keytruda and a broader
5 January 2026
··
1 … 22 23 24 25 26 … 56

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop